Vericel Corp

Cambridge

498 Total Employees

Year Founded: 1989

View Website

Vericel Corp Company Growth, Stability & Outlook

Updated on November 11, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Vericel Corp and has not been reviewed or approved by Vericel Corp.

What's the stability & growth outlook for Vericel Corp?

Strengths in revenue growth, profitability, and capital position are accompanied by exposure to variability in Burn Care, portfolio concentration, and near-term margin pressures from investment. Together, these dynamics suggest robust, finance-backed expansion with some execution and concentration risks that could influence consistency of results.

Key Insight for Candidates

Defining tradeoff: cash-rich, profitable growth anchored by MACI’s consistent 20%+ expansion, offset by Burn Care’s inherently lumpy demand. This means ample resources, rising guidance, and aggressive scaling, but also quarter-to-quarter variability and shifting priorities—suited to candidates comfortable with fast execution amid occasional volatility.

Evidence in Action

MACI Growth Scorecards — MACI net revenue rose 21% to $67.4 million, marking its sixth consecutive quarter of 20%+ growth. Teams rally around a clear product growth engine, aligning sales, clinical operations, and manufacturing to sustain momentum and plan headcount with confidence.
Debt-Free Cash Discipline — The balance sheet shows $235.6 million in cash and investments and no debt. This underpins job stability and lets teams invest in capacity, tools, and hiring without financing uncertainty.

Positive Themes About Vericel Corp

Strong Revenue Growth: Feedback suggests total net revenue increased 26% year over year to $85.4 million, with year-to-date revenue also up 26% to $231.3 million. Segment momentum is highlighted by MACI growth of 21% and Burn Care growth of 52% in the quarter.
Profitability: Net income is considered to have risen 179% to $14.2 million, while adjusted EBITDA increased 48% to $25.2 million. Margin outlook was lifted alongside raised full-year guidance.
Investor Backing & Capital Strength: Cash and investments are described at approximately $235.6 million with no debt, supporting continued investment and expansion. This balance sheet position indicates capacity to fund growth initiatives.

Considerations About Vericel Corp

Short-Term or Unsustainable Growth: Burn Care performance is viewed as potentially uneven due to dependence on unpredictable burn incidents and government procurement that may not recur. Such variability could make quarterly results volatile despite strong underlying momentum.
Operational Inefficiency: Investments in manufacturing, sales expansion, and international launches are noted as potential pressures on margins in the near term. This spending could temporarily dilute operating leverage as growth initiatives scale.
Undiversified Revenue Streams: The business is seen as concentrated in a small number of products, particularly MACI, and mainly within the U.S. This concentration may heighten sensitivity to product-specific or market-specific shifts.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.